Calidi Biotherapeutics, Inc. (CLDI) is an innovative clinical-stage biotechnology company headquartered in San Diego, California, focused on advancing immunotherapies for cancer treatment. The company's proprietary platform utilizes genetically modified oncolytic viruses to selectively target and destroy cancer cells while enhancing the body's immune response. With a strong emphasis on developing novel therapeutic solutions in the evolving field of immuno-oncology, Calidi is positioned to address significant unmet medical needs in cancer care. The firm’s cutting-edge research and promising clinical trials highlight its commitment to pioneering effective cancer treatments.

NYSE MKT

USA

HEALTHCARE

BIOTECHNOLOGY

4475 EXECUTIVE DRIVE, SAN DIEGO, CA, UNITED STATES, 92121

December

$8.56 Million

-$19.5 Million

0.0

-0.2

$0.00

0.0%

1.073